文献速递血管炎

急性小血管炎重症监护患者23年单中心结局分析

Outcomes of intensive care patients with acute small-vessel vasculitis: a 23-year single-centre experience.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

OBJECTIVES: Patients with fulminant small-vessel vasculitis (SVV) may require intensive care unit (ICU) admission, where mortality is high.…

要点

  • 重症小血管炎ICU患者30天和90天死亡率分别为15%和26%。
  • 90天存活者中新发终末期肾病发生率为28%。
  • 环磷酰胺、利妥昔单抗和血浆置换治疗与90天及长期生存相关。

核心结论

  • 该单中心23年研究报道了暴发性小血管炎ICU患者的结局,30天和90天ICU死亡率与其他报道值相当,死亡率改善与血管炎治疗方案变化相关。

研究设计与样本

  • 对患者亚组进行了1:4匹配病例对照分析,校正年龄、性别、APACHE II评分和入院年份。

主要发现

  • 30天死亡率为15%,90天死亡率为26%;90天存活者中17例(28%)发生新发终末期肾病。
  • 血管炎治疗包括环磷酰胺(59%)、利妥昔单抗(53%的AAV患者)和血浆置换(71%),这些治疗与90天和长期生存相关。
  • 2008年后接受的血管炎治疗与90天和长期生存相关,而ICU对照组中未见相应变化,该现象与血管炎服务和治疗策略的改进同时发生。

临床怎么用

  • 对于因暴发性小血管炎入住ICU的患者,应关注高APACHE II评分、通气支持和肾脏替代治疗需求,并警惕90天存活者中新发终末期肾病的风险。
  • 环磷酰胺、利妥昔单抗和血浆置换等血管炎治疗与改善90天及长期生存相关,2008年后治疗策略改进与生存改善相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with fulminant small-vessel vasculitis (SVV) may require intensive care unit (ICU) admission, where mortality is high. We describe outcomes and prognostic factors in ICU patients with ANCA-associated vasculitis (AAV) and anti-glomerular basement membrane (anti-GBM) disease over a 23-year period. METHODS: Patients admitted with acute manifestations of new or flaring AAV or anti-GBM disease were identified from our hospital ICU database (1999-2022). Patients treated solely in high-dependency areas were excluded. Primary outcomes were mortality at 30 and 90 days and development of end-stage kidney disease (ESKD). A matched case-control analysis (1:4) adjusted for age, gender, APACHE II score and admission year was performed for a patient subgroup. RESULTS: Eighty-five cases (82% AAV, 15% anti-GBM) were identified, 80% newly diagnosed. Median APACHE II score was 19. Ventilatory support and continuous venovenous haemodiafiltration were required in 92% and 66% of cases, respectively. Thirty-day and 90-day mortality rates were 15% and 26%, respectively. Among 90-day survivors, 17 (28%) developed new ESKD. Vasculitis treatments included cyclophosphamide (59%), rituximab (53% of AAV patients) and plasma exchange (71%). These treatments were associated with 90-day and long-term survival. Treatment for vasculitis post-2008 was associated with 90-day and long-term survival, which was not mirrored in ICU controls. This coincided with improvements to the vasculitis service and therapeutic strategies. CONCLUSION: This single-centre study reports ICU outcomes for patients with fulminant SVV over 23 years. Thirty-day and 90-day ICU mortality were comparable to other reported values. Improvement in mortality was associated with changes in vasculitis treatment protocols.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dierker Viik A, Xu Y, McGovern D, et al. Outcomes of intensive care patients with acute small-vessel vasculitis: a 23-year single-centre experience. Rheumatology (Oxford). 2026. PMID: 42773518. doi:10.1093/rheumatology/keag531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。